Welcome to our dedicated page for Biovaxys Technol news (Ticker: BVAXF), a resource for investors and traders seeking the latest updates and insights on Biovaxys Technol stock.
BioVaxys Technology Corp. (BVAXF) is a clinical-stage biopharmaceutical company advancing novel immunotherapies through its proprietary DPX™ delivery system and HapTenix© neoantigen technology. This page provides investors and industry observers with comprehensive updates on material developments across the company's oncology and infectious disease programs.
Our curated news feed delivers timely updates on clinical trial progress, regulatory milestones, and strategic partnerships related to BioVaxys' immune-educating platforms. Users will find verified information about vaccine candidate developments, intellectual property expansions, and peer-reviewed research findings.
Key content categories include updates on DPX™-based vaccine formulations, HapTenix© neoantigen constructs, and preclinical/clinical study results. All content is sourced from official company communications and reputable financial/news outlets to ensure reliability.
Bookmark this page for streamlined access to BioVaxys' latest developments in targeted immunotherapy. Check regularly for updates on technology licensing agreements, trial phase advancements, and scientific publications demonstrating platform efficacy.
BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTC: BVAXF) announced the revocation of a cease trade order issued by the Ontario Securities Commission (OSC) on May 15, 2024. The order was due to delays in filing audited annual financial statements for the year ended October 31, 2023, and interim financial statements for the three months ended January 31, 2024. The company has now completed these filings, along with interim financial statements for the six months ended April 30, 2024. The OSC confirmed the order revocation on July 11, 2024, with all filings available on SEDAR+.
BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) has been issued a Failure-to-File Cease Trade Order (FFCTO) by the Ontario Securities Commission (OSC) due to delays in filing required financial statements and discussions for the fiscal year ending October 31, 2023, and the three months ending January 31, 2024. The FFCTO, effective May 15, 2024, prohibits any trading of BioVaxys securities in Canada. The company missed deadlines of February 28, 2024, for annual filings and April 1, 2024, for interim filings. They are working to complete these filings soon and expect the FFCTO to be lifted once compliance is achieved.
BioVaxys Technology Corp. appoints Christopher Cherry as Chief Financial Officer, bringing extensive experience in financial management. The company anticipates significant growth following the recent acquisition of IMV Intellectual Property.
FAQ
What is the current stock price of Biovaxys Technol (BVAXF)?
What is the market cap of Biovaxys Technol (BVAXF)?
